Thomas L Richie

Title: The Innovations of Thomas L Richie

Introduction

Thomas L Richie is a notable inventor based in Glenelg, MD (US), recognized for his contributions to the field of immunology. He holds a total of five patents, showcasing his innovative approach to vaccine development and pathogen-specific treatments. His work has significant implications for public health and disease prevention.

Latest Patents

Richie's latest patents include the TH1/TH2 polarizing vaccines, which involve recombinant chimeric molecules designed to enhance T cell receptor interaction and costimulation. This innovation aims to activate and differentiate pathogen-specific T cells into effector T helper 1 (Th1) or T helper 2 (Th2) cells. Additionally, these chimeric molecules can elicit antibodies against specific B cell epitopes, providing a robust method for vaccine formulation. Another significant patent focuses on novel malaria polypeptides expressed during the pre-erythrocytic stage of the malaria life-cycle. These antigens are intended to induce an immune response against malaria in mammals, either through vaccine formulations or by utilizing DNA and other nucleic acid expression systems.

Career Highlights

Richie is currently associated with the United States Navy, where he contributes his expertise in vaccine research and development. His work is pivotal in advancing military and civilian health initiatives, particularly in combating infectious diseases.

Collaborations

Some of his notable coworkers include Sofia A Casares and Teodor D Brumeanu, who collaborate with him on various research projects aimed at enhancing vaccine efficacy and safety.

Conclusion

Thomas L Richie exemplifies the spirit of innovation in the field of immunology, with his patents paving the way for new vaccine technologies. His contributions are vital for improving health outcomes and addressing global health challenges.